Monopar Therapeutics (MNPR) Net Cash Flow: 2016-2024
Historic Net Cash Flow for Monopar Therapeutics (MNPR) over the last 9 years, with Dec 2024 value amounting to $38.5 million.
- Monopar Therapeutics' Net Cash Flow rose 967.33% to $5.4 million in Q3 2020 from the same period last year, while for Sep 2020 it was $13.5 million, marking a year-over-year increase of 533.08%. This contributed to the annual value of $38.5 million for FY2024, which is 4367.57% up from last year.
- Latest data reveals that Monopar Therapeutics reported Net Cash Flow of $38.5 million as of FY2024, which was up 4,367.57% from -$903,318 recorded in FY2023.
- In the past 5 years, Monopar Therapeutics' Net Cash Flow ranged from a high of $38.5 million in FY2024 and a low of -$12.1 million during FY2022.
- Moreover, its 3-year median value for Net Cash Flow was -$903,318 (2023), whereas its average is $8.5 million.
- Per our database at Business Quant, Monopar Therapeutics' Net Cash Flow slumped by 440.08% in 2022 and then soared by 4,367.57% in 2024.
- Monopar Therapeutics' Net Cash Flow (Yearly) stood at $3.5 million in 2020, then rose by 1.20% to $3.6 million in 2021, then crashed by 440.08% to -$12.1 million in 2022, then soared by 92.54% to -$903,318 in 2023, then surged by 4,367.57% to $38.5 million in 2024.